A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy - Green, M D; Koelbl, H; Baselga, J; Galid, A; Guillem, V; Gascon, P; Siena, S; Lalisang, R I; Samonigg, H; Clemens, M R; Zani, V; Liang, B C; Renwick, J; Piccart, M J (Ann Oncol, 2003)
PM:12488289